ClinicalTrials.gg
RecruitingNCT07741253PRECISE-AFMR IUpdated Oct 26, 2026

PRECISE-AFMR I: Transcatheter Mitral Valve Edge-to-Edge Repair for Atrial Functional Mitral Regurgitation in Patients at High Surgical Risk

An interventional study of Transcatheter Edge-to-Edge Repair in Atrial Functional and Mitral Regurgitation (MR), sponsored by China National Center for Cardiovascular Diseases. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by China National Center for Cardiovascular Diseases · Not applicable, Interventional, and Treatment

How we know

Updated Oct 26, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Mitral Valve Insufficiency with a site in China — 44 open to participants now, 46 under way, none of them phase 3. Mitral Valve Insufficiency · China.

Planned enrollment
10th of 40
182 · median 127
Started
2026
with 7 others
No phase
36 of 57
29 open now
Primary completion
2027-12
later than 33 of 45 live
Registered
52nd of 57
by date
Lead sponsor
6 of 57
China National Center for Cardiovascular Diseases

Among the 57 studies in Mitral Valve Insufficiency with a site in China, this one is the 10th largest by planned enrollment of the 40 interventional ones that give a count, is one of 8 that started in 2026, is one of 36 with no phase, reaches primary completion later than 33 of the 45 other live ones, and was the 52nd registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

44 of the 57 studies in Mitral Valve Insufficiency with a site in China are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Mitral Valve Insufficiency with a site in China, or all of them as a file.
02

Study summary

Atrial functional mitral regurgitation (AFMR) develops when enlargement and remodeling of the left atrium and mitral annulus prevent the mitral valve leaflets from closing completely, allowing blood to leak backward through the valve. For patients with significant AFMR who remain symptomatic despite medical treatment and are at high risk for surgery, it is uncertain whether adding transcatheter mitral valve edge-to-edge repair (TEER), a catheter-based procedure that brings the mitral valve leaflets together, provides better outcomes than medical treatment alone.

PRECISE-AFMR I is a prospective, multicenter, randomized study that will enroll 182 adults with moderate-to-severe or severe AFMR, high or prohibitive surgical risk, and mitral valve anatomy suitable for TEER. Participants will be assigned in a 1:1 ratio to receive TEER plus optimized guideline-directed medical therapy (GDMT) or optimized GDMT alone. All participants will receive standardized medical care and will be followed for 12 months.

The main effectiveness outcome is the occurrence of death from any cause or hospitalization for heart failure within 12 months. The main safety outcome is the occurrence of major device-related adverse events within 12 months. The study will also assess mitral regurgitation severity, symptoms, functional capacity, quality of life, heart failure events, and use of health care resources.

Read the detailed description

PRECISE-AFMR I is designed to address the limited randomized evidence for transcatheter edge-to-edge repair (TEER) in patients with atrial functional mitral regurgitation (AFMR). The study uses standardized phenotypic and imaging assessment to identify patients in whom AFMR is the predominant mechanism of mitral regurgitation and whose mitral valve anatomy is considered suitable for TEER.

Before randomization, each participant will provide written informed consent and undergo clinical, laboratory, and imaging assessments. Echocardiographic data will be submitted to an independent echocardiography core laboratory (ECL) for confirmation of the AFMR diagnosis, mitral regurgitation severity, left ventricular function, left atrial remodeling, and anatomical suitability for TEER. An eligibility committee will then review the clinical findings, surgical risk, prior treatment, and ECL assessment. Only participants confirmed as eligible by both the ECL and the eligibility committee will proceed to randomization.

Eligible participants will be randomly assigned in a 1:1 ratio to TEER plus optimized guideline-directed medical therapy (GDMT) or optimized GDMT alone. Randomization will be performed through a central randomization system or electronic data capture system using blocked randomization stratified by study center or center group. The allocation sequence will be generated and maintained independently, and treatment assignment will not be released until eligibility and baseline assessments have been completed.

Because TEER is an interventional procedure, participants and treating investigators will not be blinded to treatment assignment. To reduce potential assessment bias, key echocardiographic measurements will be centrally reviewed by the ECL, and major clinical and safety events will be adjudicated by an independent clinical events committee that is blinded to treatment assignment whenever feasible. Both groups will receive comparable follow-up intensity, event collection, heart failure management, atrial fibrillation management, anticoagulation or antiplatelet therapy when clinically indicated, and management of comorbid conditions.

Participants assigned to the TEER group will undergo the procedure in addition to continued optimized GDMT and standardized clinical care. TEER is intended to be performed as soon as clinically feasible after randomization, preferably within 14 days and, when medically delayed, within 30 days whenever possible. Participants assigned to the control group will not undergo planned TEER before completion of the 12-month primary evaluation period and will receive individualized optimization of GDMT and other indicated standard treatments.

All randomized participants will be followed for 12 months, with major assessments conducted at baseline, treatment or discharge, 30 days, 6 months, and 12 months. Rescue TEER or another necessary intervention may be considered for participants in the GDMT group who experience clinically significant deterioration despite optimized treatment. Such treatment will require reassessment by the heart team, confirmation that the anticipated benefit outweighs the risk, and renewed informed consent. Rescue treatment and crossover events will be fully documented, while the primary efficacy analysis will follow the intention-to-treat principle.

Study data will be collected using standardized case report forms or an electronic data capture system. The ECL will centrally review key imaging outcomes, the clinical events committee will adjudicate major clinical and safety events, and an independent data and safety monitoring board will periodically review participant safety and study conduct.

03

Conditions studied

  • Atrial Functional
  • Mitral Regurgitation (MR)

Keywords

  • Atrial functional mitral regurgitation
  • Transcatheter edge-to-edge repair
  • TEER
  • MitraClip
  • Guideline-directed medical therapy
  • High surgical risk
  • Secondary mitral regurgitation
  • Heart failure hospitalization
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Aged ≥18 years;

    2. Presence of symptoms of heart failure, with (NYHA) functional class II, III, or ambulatory class IV;

    3. Confirmed by preliminary assessment of the study-site Heart Team and review by the Echocardiography Core Laboratory (ECL) to have at least moderate-to-severe atrial functional mitral regurgitation (AFMR), generally graded as 3+ or 4+;

    4. At least one hospitalization for heart failure within the 12 months prior to enrollment and/or a plasma B-type natriuretic peptide (BNP) level ≥300 pg/mL or N-terminal pro-B-type natriuretic peptide (NT-proBNP) level ≥1,500 pg/mL;

    5. As confirmed by a heart failure specialist at the study site, the subject has received maximally optimized guideline-directed medical therapy (GDMT) and other necessary standardized comprehensive treatment in accordance with current guidelines for at least 3 months. For subjects with concomitant atrial fibrillation, coronary artery disease, or other potentially correctable comorbidities, appropriate evaluation and guideline-recommended management must have been completed, or the subject must have been clearly determined to be unsuitable for further treatment;

    6. Determined by the multidisciplinary Heart Team, in accordance with the process described in Section 4.7, to be at high surgical risk, to have a to surgery, or to be unsuitable for surgery, or determined after comprehensive assessment that surgical treatment is not the optimal current strategy;

    7. During the screening period or within 90 days prior to randomization, mitral valve anatomy is assessed by echocardiography at the study site and confirmed by the ECL to be suitable for transcatheter edge-to-edge repair (TEER). Anatomical suitability must meet at least all of the following criteria:

    • Mitral valve area >4.0 cm² and baseline mean transmitral pressure gradient \<4 mmHg;

      • Adequate mobility or sufficient graspable leaflet tissue in the target grasping area, with a mobile/graspable leaflet length ≥10 mm;

        • Mitral annular anteroposterior diameter ≤40 mm;

          • Left atrial volume index (LAVI) \<85 mL/m²;

            ⑤ Leaflet-to-annulus index (LAI) >1.10;

            8. The transseptal puncture route and femoral venous access are considered suitable for TEER by the investigator or Heart Team;

            9. The subject or the subject's legally authorized representative voluntarily agrees to comply with the requirements of the study protocol, including the possibility of being randomized to the optimized GDMT group, and provides written .

Exclusion criteria

Exclusion Criteria:

  • 1. Presence of primary structural mitral valve disease that can independently account for the mitral regurgitation (MR), such as leaflet prolapse, flail leaflet, rheumatic valvular disease, leaflet perforation, or damage resulting from infective endocarditis;

    2. Functional mitral regurgitation other than atrial functional mitral regurgitation (AFMR), including ventricular functional mitral regurgitation caused by left ventricular dilatation, regional wall-motion abnormalities, ischemic cardiomyopathy, dilated cardiomyopathy, or other conditions involving the myocardium, including restrictive cardiomyopathy, hypertrophic cardiomyopathy, and infiltrative cardiomyopathy such as amyloidosis, hemochromatosis, or sarcoidosis;

    3. Presence of pericardial disease, such as constrictive pericarditis, that may be the predominant mechanism underlying heart failure or MR;

    4. Prior surgical mitral valve intervention or transcatheter mitral valve intervention;

    5. Concomitant moderate-to-severe or greater disease of another heart valve requiring surgical or transcatheter intervention;

    6. An acute cerebrovascular event within the previous 30 days;

    7. Cardiovascular or cerebrovascular surgery or interventional treatment within the previous 30 days, including coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI), transcatheter aortic valve replacement (TAVR), or transcatheter carotid artery stenting;

    8. Severe symptomatic carotid artery stenosis, defined as >70% stenosis on ultrasonography;

    9. Hemodynamic instability requiring continuous intravenous drug infusion or mechanical circulatory support;

    10. Pulmonary artery systolic pressure (PASP) >70 mmHg as estimated by echocardiography, or pulmonary vascular resistance (PVR) >3 Wood units as measured by right heart catheterization;

    11. Symptoms, signs, or echocardiographic evidence of severe right ventricular dysfunction, such as tricuspid annular plane systolic excursion (TAPSE) \<15 mm or peak systolic tissue Doppler velocity (S') \<10 cm/s;

    12. Chronic renal insufficiency requiring long-term hemodialysis;

    13. Severe liver cirrhosis accompanied by esophageal varices;

    14. Prior heart transplantation;

    15. Severe (COPD) requiring continuous home oxygen therapy or long-term oral therapy;

    16. Severe hematologic disease;

    17. A modified Rankin Scale score ≥4, indicating moderately severe or severe disability;

    18. Mitral valve anatomical features that, as assessed by echocardiography at the study site and confirmed by the Echocardiography Core Laboratory (ECL), may prevent safe implantation, appropriate positioning, stable leaflet grasping, or adequate reduction of MR with the transcatheter edge-to-edge repair (TEER) device. Such features include, but are not limited to, insufficient leaflet mobility or insufficient graspable leaflet tissue in the target grasping area, significant calcification in the grasping area, a prominent leaflet cleft, leaflet perforation, severe leaflet thickening, fibrosis, retraction, or severely restricted leaflet mobility, insufficient primary or secondary chordal support, or any other anatomical feature that, in the judgment of the ECL, may result in technical failure of TEER, significant residual MR, or an increased risk of mitral stenosis after the procedure;

    19. An intracardiac mass, thrombus, or vegetation detected by echocardiography;

    20. A to, or a high risk associated with, transesophageal echocardiography;

    21. Inadequate echocardiographic image quality;

    22. Known allergy or contraindication to any medication or device material required for the TEER procedure;

    23. Pregnancy, breastfeeding, or intention to become pregnant within the following 12 months;

    24. Anticipated need for emergency surgery or elective cardiac surgery for any reason within the following 12 months;

    25. of \<12 months due to a noncardiac condition;

    26. The subject is a member of a vulnerable population or has a condition that may impair their ability to provide written and/or comply with study procedures;

    27. Current participation in another interventional drug or device trial that may interfere with the assessment of the primary endpoint of this study;

    28. Any other condition that, in the judgment of the investigator, ECL, or EC, renders the subject unsuitable for participation in this study.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
182 participants (estimated)

Study arms

  • Experimental
    TEER plus optimized GDMT group

    Device: Transcatheter Edge-to-Edge Repair

  • No intervention
    Optimized GDMT group

Interventions

  • DeviceTranscatheter Edge-to-Edge Repair

    Transcatheter edge-to-edge repair (TEER) reduces mitral regurgitation by approximating the anterior and posterior mitral leaflets, increasing the leaflet coaptation area, and reducing the regurgitant orifice area.

06

What researchers measure

Primary outcomes

  1. Composite endpoint of all-cause mortality or hospitalization for heart failure within 12 months after randomization.

    Time frame: Within 12 months after randomization.

  2. Composite endpoint of device-related major adverse events.

    * Single leaflet device attachment (SLDA); * Device migration, device embolization, device detachment, or device fracture; * Device thrombosis; * Device-related infective endocarditis; * Mitral stenosis requiring surgical treatment or an unplanned repeat intervention; * Non-elective cardiac surgery or unplanned repeat mitral valve intervention due to a device-related complication; * Left ventricular assist device implantation; * Heart transplantation; * Other serious device-related complications adjudicated by the Clinical Events Committee (CEC) as device-related major adverse events in accordance with the Mitral Valve Academic Research Consortium (MVARC) criteria.

    Time frame: Within 12 months after randomization.

Secondary outcomes

  1. Hierarchical composite endpoint of all-cause mortality, hospitalization for heart failure, or urgent emergency department/outpatient intensification of heart failure therapy within 12 months after randomization

    Time frame: within 12 months after randomization

  2. Proportion of patients with MR ≤1+ at 30 days, 6 months, and 12 months

    Time frame: 30 days, 6 months, and 12 months

  3. Proportion of patients with MR ≤2+

    Time frame: 30 days, 6 months, and 12 months

  4. Residual MR grade and change from baseline

    Time frame: 30 days, 6 months, and 12 months

  5. Change in NYHA functional class and proportion of patients in NYHA class I/II

    Time frame: 30 days, 6 months, and 12 months

  6. Change from baseline in left atrial anteroposterior diameter

    Time frame: at 12 months

  7. Change from baseline in left atrial volume index (LAVI)

    Time frame: at 12 months

  8. Change from baseline in 6-minute walk distance (6MWD)

    Time frame: at 12 months

  9. Change from baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) score

    Time frame: at 12 months

  10. Change from baseline in BNP or NT-proBNP level

    Time frame: at 12 months

  11. Number of recurrent hospitalizations for heart failure

    Time frame: within 12 months after randomization

  12. All-cause mortality

    Time frame: within 12 months after randomization

  13. Cardiovascular mortality

    Time frame: within 12 months after randomization

  14. Non-cardiovascular mortality

    Time frame: within 12 months after randomization

  15. First hospitalization for heart failure

    Time frame: within 12 months after randomization

  16. Total number of hospitalizations for heart failure

    Time frame: within 12 months after randomization

  17. Emergency department visits or outpatient events requiring intensification of heart failure therapy

    Time frame: within 12 months after randomization

  18. Composite endpoint of major procedure-related adverse events

    The composite endpoint includes, but is not limited to, any of the following: All-cause mortality; Stroke, including ischemic stroke and hemorrhagic stroke, or transient ischemic attack; Acute myocardial infarction; Non-elective cardiac surgery due to device- or procedure-related complications; Life-threatening or major bleeding; Major vascular complications; Stage 2 or 3 acute kidney injury, including new initiation of dialysis; Cardiac tamponade or pericardial effusion requiring interventional or surgical treatment; Clinically significant iatrogenic atrial septal defect requiring treatment; Other serious adverse events adjudicated by the Clinical Events Committee (CEC) as major procedure-related adverse events in accordance with the Mitral Valve Academic Research Consortium (MVARC) criteria.

    Time frame: within 30 days after the TEER procedure

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Dec 2027, 14 months later.

Of 144 interventional studies with no phase under Mitral Valve Insufficiency, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 108. This study's planned 14 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, on Oct 26, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2026
First posted
Aug 3, 2026
StartEst.
Oct 25, 2026was Aug 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 26, 2026
Sites
Fuwai Hospital is now Recruiting
Oct 26, 2026
Start date
Aug 2026→Oct 25, 2026
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Not yet recruiting→Recruiting
    Fuwai Hospital is now Recruiting
    Start date Aug 2026→Oct 25, 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07741253
Responsible party
Sponsor
First posted
Aug 3, 2026
Start date
Oct 25, 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

Zhinan Lu
Contact
lzn1982hy@163.com
+86 18600268732

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion